Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

The aim of this study was to assess postprandial glycaemic outcomes using automated insulin delivery with faster acting insulin aspart (FIA) or standard insulin aspart (SIA) over 4 weeks in youth (aged 10-18 years) with type 1 diabetes.

Who Took Part

The age groups tagged for this paper are children and teenagers, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Insulin Aspart.

In the crossover set-up each of the participants took both Insulin Aspart and the comparison in turn, acting as their own control.

The timeline in the abstract includes 4 weeks.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 1, Insulin Aspart, Postprandial Period, Hypoglycemic Agents, Blood Glucose, Insulin Infusion Systems and Glycated Hemoglobin.

Author keywords: continuous glucose monitoring (CGM), glycaemic control, insulin therapy and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart over 4 weeks.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page, all human trials.